Ascelia Pharma appoints Julie Waras Brogren as Chief Commercial Officer

Ascelia Pharma AB (publ) (ticker: ACE) today announced that Julie Waras Brogren has been appointed as Chief Commercial Officer (CCO) of Ascelia Pharma. Julie will be a member of the Executive Management and will start in the beginning of January 2020.

The appointment of Julie Waras Brogren as CCO marks an important step for Ascelia Pharma as the company is approaching commercial stage. With more than 18 years of extensive leadership experience in global product launches, market access and life cycle management from senior roles in the biopharma and medtech industries, Julie brings in-depth commercial experience spanning multiple therapeutic areas, brands, and geographies.

Before joining Ascelia, Julie was Chief Operating Officer and later President of the Toronto-based medical company BresoTEC. Prior to that, she held a number of senior positions at Novo Nordisk in Denmark and Brazil, including Head of Marketing & Market Access in the Latin America Region and part of the Latin America Management team. Julie was instrumental in the launch preparations and the cross-functional pre-commercialization of the multi-blockbuster drug liraglutide (Victoza®) and insulin degludec (Tresiba®). She holds an MBA from Copenhagen Business School and an MSc from Ecole de Management de Lyon.

“We are extremely pleased to add Julie to our team. With her long experience and excellent track record in global product launches and launch preparations, for highly successful products such as Victoza®, Julie will be instrumental in leading our commercial preparations for the launch of our lead candidate Mangoral, which is planned for 2022,” said Magnus Corfitzen, CEO of Ascelia Pharma.

“I am very happy to join Ascelia Pharma at this interesting and exciting phase of the company’s development and to take an active role in driving the transformation to become a commercial stage company. I see great opportunities for our drugs in the pipeline, and I look forward to leading the commercial organization and bring these important products to patients living with clear unmet needs globally,” said Julie Waras Brogren.

For more information, please contact:
Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel. 46 735 179 110

Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 7.30 a.m. CET on 6 December 2019.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.

About Us

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development. Mangoral is a novel contrast agent for MR-scans in Phase III clinical studies. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com

Subscribe

Quick facts

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development. Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com
Tweet this